BRIEF published on 10/10/2024 at 07:05, 1 month 11 days ago Valneva presents its outlook at an investor day in New York Investors Growth Valneva Vaccines Lyme
PRESS RELEASE published on 10/10/2024 at 07:00, 1 month 11 days ago Valneva Hosts Investor Day in New York City Valneva SE is hosting an investor day in New York City to discuss key value drivers, including Lyme disease vaccine, commercial vaccines, and R&D pipeline. Hybrid event with webcast and Q&A sessions Investor Day Valneva SE Lyme Disease Vaccine R&D Pipeline Commercial Vaccines
BRIEF published on 10/04/2024 at 07:35, 1 month 17 days ago Valneva SE Announces Changes in Shares and Voting Rights Euronext Paris Voting Rights Shares Capital Increase Valneva SE
PRESS RELEASE published on 10/04/2024 at 07:30, 1 month 17 days ago Valneva SE - Declaration of shares and voting rights - September 30, 2024 Valneva declares changes in shares and voting rights, including a transfer into bearer form and a capital increase without preferential subscription rights Voting Rights Shares Capital Increase Transfer Valneva
BRIEF published on 10/03/2024 at 07:05, 1 month 18 days ago Valneva to Hold Investor Day in New York New York Investors Valneva Vaccines Chikungunya
PRESS RELEASE published on 10/03/2024 at 07:00, 1 month 18 days ago Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET Valneva SE to host Investor Day at Lotte New York Palace Hotel on Thursday, October 10, 2024, focusing on R&D pipeline and revenue-generating vaccines Investor Day Valneva SE Vaccine R&D Pipeline Lotte New York Palace Hotel
BRIEF published on 09/23/2024 at 15:51, 1 month 27 days ago Valneva Bolstered by Capital Raise Amid Strategic Focus on Vaccine Development BUY Rating Valneva SE Vaccine Development Equity Research Capital Raise
PRESS RELEASE published on 09/23/2024 at 15:46, 1 month 27 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Valneva SE (FR0004056851) with a BUY rating and a decreased price target to €7.70, reflecting the recent capital raise completed on 13 September 2024 BUY Rating Price Target Valneva SE Equity Research Capital Raise
BRIEF published on 09/23/2024 at 10:59, 1 month 27 days ago Bpifrance crosses the threshold of 10% of VALNEVA voting rights downwards Capital AMF Valneva Threshold Crossing Bpifrance
BRIEF published on 09/23/2024 at 10:58, 1 month 27 days ago Threshold Crossing at VALNEVA SE by Bpifrance Capital Valneva CDC Threshold Crossing Bpifrance
Published on 11/21/2024 at 10:03, 29 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 32 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 32 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 57 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 7 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 27 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 29 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 32 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 32 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 31 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 34 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 12 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 47 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 47 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
